ATG16L1 and Crohn disease: Furthermore, we have also seen that Crohn's disease patients that were homozygous carriers of the ATG16L1 T300A SNP responded better to thiopurine therapy than Crohn's disease patients that carried at least one wild-type (WT) ATG16L1 allele (Wildenberg et al., 2017).